Search Orphan Drug Designations and Approvals
-
Generic Name: | a fixed-dose combination containing two active ingredients, senaparib and temozolomide |
---|---|
Date Designated: | 08/03/2022 |
Orphan Designation: | Treatment of Small Cell Lung Cancer |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
IMPACT Therapeutics, Inc. 12F, New Bund Times Square, 399 Haiyang West Rd. Pudong District Shanghai China The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-